Sobi™ Satellite Symposium

 

Agenda

Chair’s welcome - Marina Vivarelli, Italy
C3G and primary IC-MPGN: An urgent need to improve patient care - Marina Vivarelli, Italy
Focusing on C3: The common disease mechanism in a heterogeneous patient population - Matthew Pickering, UK
A new treatment paradigm: Complement inhibition in C3G and primary IC-MPGN - Fadi Fakhouri, Switzerland
Closing remarks and Q&A - Marina Vivarelli, Italy

Publication
  • ERA •
  • 6 June, 2025 •
  • •

Pegcetacoplan demonstrates clinically significant responses in C3G and Primary (Idiopathic) IC-MPGN patients with or without concomitant immunosuppression in VALIANT

David Kavanagh, Andrew S Bomback, Gema Ariceta, Antonio Mastrangelo, Carla M Nester, Giuseppe Remuzzi, Marina Vivarelli, Zhongshen Wang, Johan Szamosi, Dima Decker, Lucía Quintana-Gallardo, Fadi Fakhouri

Available materials

Oral Presentation
Publication
  • ERA •
  • 6 June, 2025 •
  • •

Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or Primary (Idiopathic) IC-MPGN

Marina Vivarelli, Andrew S Bomback, Gema Ariceta, Antonio Mastrangelo, Carla M Nester, Giuseppe Remuzzi, Nicole Van De Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lucía Quintana-Gallardo, Fadi Fakhouri

Available materials

Oral Presentation
Publication
  • ERA •
  • 6 June, 2025 •
  • •

Targeted treatment with pegcetacoplan for adolescents with C3G or Primary (Idiopathic) IC-MPGN in the VALIANT phase 3 trial

Antonio Mastrangelo, Marina Vivarelli, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Christoph Licht, Nabil Melhem, Nicole Van De Kar, Dean Wallace, Li Li, Luis López Lázaro, Carla M Nester

Available materials

Oral Presentation
Publication
  • ERA •
  • 6 June, 2025 •
  • •

Pegcetacoplan treatment appears to halt disease progression in C3G and Primary (Idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study

Daniel P Gale, Andrew S Bomback, Christoph Licht, Carla M Nester, Matthew C Pickering, Giuseppe Remuzzi, Nicole Van De Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lucía Quintana-Gallardo, Fadi Fakhouri

Available materials

Poster
Publication
  • ESPN •
  • 17 October, 2025 •
  • •

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary ​ IC-MPGN: Phase 3 VALIANT study results

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Nayoa Fujita, Larry A Greenbaum, Antonio Mastrangelo, Nabil Melhem, Nicole CAJ Van de Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Katie Gordon, Zhongshen Wang, Carla M Nester

Publication
  • ESPN •
  • 16 October, 2025 •
  • •

Pegcetacoplan for paediatric patients with​ C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Nicole CAJ Van de Kar, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Larry A Greenbaum, Christoph Licht, Antonio Mastrangelo, Nabil Melhem, Nayoa Fujita, Dean Wallace, Marina Vivarelli, Zhongshen Wang, Dima Decker, Johan Szamosi, Lucía Quintana-Gallardo, Carla M Nester

Publication
  • IPTA •
  • 18 September, 2025 •
  • •

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials

Poster
Publication
  • WTC •
  • 2 August, 2025 •
  • •

Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials

Oral Presentation
Sign up for alerts